September 2018: Hep Headlines

11 Sep 2018 Chris Wingrove

Hepatitis is making the news regularly thanks to the work of WHA members, here are a few highlights

First ever conference on ehealth and the elimination of viral hepatitis

WHA member, the Chennai Liver Foundation, hosted the first ever Summit on ‘eHealth & the Elimination of Viral Hepatitis’ on 11th August 2018 in India. The conference was opened by WHA
CEO Raquel Peck who emphasised the important role of Civil Society giving examples of how patient groups are using innovation to enhance the elimination response

Rwanda offers regular tests and vaccines to eliminate hepatitis

Rwanda’s Minister of health, Diane Gashumba says the country regards viral hepatitis as a serious public health concern in the country but the Government has increased the commitment to maintain momentum to scale up screening and treatment.

FIND and DNDi team up to support Malaysian MOH efforts to simplify and decentralize hepatitis C screening & treatment

The Foundation for Innovative New Diagnostics (FIND) and the Drugs for Neglected Diseases initiative (DNDi) will partner
to generate evidence that will support policy change and scale up of hepatitis C (HCV) diagnosis and treatment in collaboration with the Ministry of Health
in Malaysia. It forms part of
a larger FIND project known as Hepatitis C Elimination through Access to Diagnostics (HEAD- Start), supported by Unitaid.


Research shows that nearly 40% of recent injection drug users are living with HCV

An international research study designed to estimate the global, regional, and national prevalence of hepatitis C virus (HCV) infection among people who inject drugs (PWID) has determined that nearly 40% (39.2%) of recent injection drug users are living with HCV. According to the study authors, the data on HCV infection burden produced by the study could assist World Health Organization (WHO) efforts to eliminate HCV as a “global public health threat by 2030,” allowing for more accurate monitoring and targeting of prevention/treatment strategies.


End-stage liver disease deaths due to hepatitis C fall in the United Kingdom and Australia

Deaths from liver failure or liver cancer caused by hepatitis C fell by 20% between 2016 and 2018 in Australia, the Kirby Institute at the University of New South Wales reported in August.
A similar trend was evident in the United Kingdom, Public Health England (PHE) reported.


Read this and much more in hepVoice

Download the PDF here (3.3mb)